Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
- 1 April 2004
- journal article
- Published by American Society of Hematology in Blood
- Vol. 103 (7), 2738-2743
- https://doi.org/10.1182/blood-2003-06-2031
Abstract
Despite the success of anti-CD20 monoclonal antibody (mAb) in the treatment of lymphoma, there remains considerable uncertainty about their mechanism(s) of action. Here, we show that certain of these reagents (rituximab and 1F5), which redistribute CD20 into membrane rafts, are bound efficiently by C1q, deposit C3b, and result in complement-dependent cytotoxicity (CDC). This activity is important in vivo, because complement depletion using cobra venom factor (CVF) markedly reduced the efficacy of rituximab and 1F5 in 2 lymphoma xenograft models. However, complement depletion had no effect on the potent therapeutic activity of B1, a mAb that does not redistribute CD20 into membrane rafts, bind C1q, or cause efficient CDC. Equivalent immunotherapy also occurred in the presence or absence of natural killer (NK) cells. Perhaps most surprising was the observation that F(ab′)2 fragments of B1 but not 1F5 were able to provide substantial immunotherapy, indicating that non-Fc-dependent mechanisms are involved with B1. In accordance with this, B1 was shown to induce much higher levels of apoptosis than rituximab and 1F5. Thus, although complement is important for the action of rituximab and 1F5, this is not so for B1, which more likely functions through its ability to signal apoptosis. (Blood. 2004;103:2738-2743)Keywords
This publication has 25 references indexed in Scilit:
- The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosusArthritis & Rheumatism, 2003
- Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid raftsBlood, 2003
- The membrane attack complex of complement induces caspase activation and apoptosisEuropean Journal of Immunology, 2002
- Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa geneBlood, 2002
- The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis inductionBlood, 2002
- Human CD38 is associated to distinct molecules which mediate transmembrane signaling in different lineagesEuropean Journal of Immunology, 1993
- The role of complement in inflammation and phagocytosisImmunology Today, 1991
- Use of the monoclonal antibody WR17, identifying the CD37 gp40–45 Kd antigen complex, in the diagnosis of B‐lymphoid malignancyThe Journal of Pathology, 1987
- Selective depletion of nk cell activity in vivo and its effect on the growth of NK‐sensitive and nk‐resistant tumor cell variantsInternational Journal of Cancer, 1982
- Role of Complement in the Induction of Immunological ResponsesImmunological Reviews, 1976